News

asco.org24d
Trastuzumab Deruxtecan Can Help Some People With Advanced Gastric Cancers Live About 3 Months Longer
The international phase 3 DESTINY-Gastric04 clinical trial found that second-line treatment with trastuzumab deruxtecan (Enhertu®) can help people with ... Sankyo for trastuzumab deruxtecan (T-DXd; DS ...
Yahoo Finance22d
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive ...
June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...
Yahoo Finance24d
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer ...
TOKYO & BASKING RIDGE, N.J., May 31, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) demonstrated a statistically ...
Morningstar24d
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer ...
Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting ENHERTU is a specifically ...
Morningstar22d
ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in ...
Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in ...
Cure Today22d
Initial Enhertu Combo Improves Survival in HER2+ Advanced Breast Cancer
Enhertu plus Perjeta improved median PFS to 40.7 months versus 26.9 months with standard care in HER2-positive breast cancer. The PFS benefit was consistent across subgroups, including hormone ...
Yahoo Finance22d
ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in ...
TOKYO & BASKING RIDGE, N.J., June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly ...
Investing21d
ENHERTU shows promise in metastatic breast cancer trial
TOKYO & BASKING RIDGE, N.J. - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) announced positive results from the phase 3 DESTINY-Breast09 trial, indicating that their drug ENHERTU®, ...
STAT22d
Enhertu, used as first option, stalled tumors for more than a year in women with breast cancer, study finds
You can reach Adam on Signal at stataf.54. CHICAGO — The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously ...
Joplin Globe22d
ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in ...
Positive results from the DESTINY-Breast09 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful ...
Investing22d
ENHERTU trial shows promise in HER2-positive breast cancer
The study revealed that ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% compared to the standard treatment of a taxane with trastuzumab and pertuzumab (THP).
Hosted on MSN28d
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
MONDAY, Feb. 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic ...